Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the covid-19 drug associated apis market grown over the years?

In the last few years, the market size for APIs associated with COVID-19 drugs has seen robust growth. The market is projected to increase from $6.75 billion in 2024 to $7.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.8%. Factors contributing to the growth during the historic period include a rising number of COVID-19 cases, enhanced understanding of treatments for COVID-19, wider availability of COVID-19 drugs, escalating demand for prophylactic COVID-19 drugs, government interventions, and resilient supply chains.

What Is the forecasted market size and growth rate for the covid-19 drug associated apis market?

The COVID-19 drug-related apis market is predicted to experience substantial growth over the next several years, augmenting to $9.08 billion in 2029 with a compound annual growth rate (CAGR) of 6.2%. The growth during the predicted period is likely due to the creation of new COVID-19 drug strategies, augmented clinical trials for COVID-19 medicines, escalating demand for COVID-19 immunizations, emerging variants, immunization campaigns, and preparation for pandemics. The noticeable trends anticipated in the forecast period comprise personalized API manufacturing, diversification of API resources, innovative manufacturing technologies, digital transformation and data analytics, environmental sustainability, and green chemistry.

Get your covid-19 drug associated apis market report here!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3248&type=smp

What are the major factors driving growth in the covid-19 drug associated apis market?

The need for active pharmaceutical ingredients (APIs) in the manufacture of COVID-19 drugs is being driven by a high demand for medications such as antiretrovirals, antimalarials, sedatives, bronchodilators, and other drugs associated with respiratory disorders. APIs represent the components with biological activity that are used in the production of pharmaceuticals. Remdesivir and Favipiravir are two commonly used antiviral drugs for COVID-19 patients, with Remdesivir having obtained emergency-use approval in the United States and Japan. The FDA has also given the green light to Airsupra (a combination of albuterol and budesonide) in aerosol form for as-needed treatment or prevention of bronchoconstriction, thereby reducing the risk of asthma attacks in patients aged 18 and above. Favipiravir, a treatment for influenza in Japan, has demonstrated a beneficial impact on COVID-19 patients. In light of COVID-19 being a respiratory disease, there has been a significant surge in demand for bronchodilators. In turn, the growing demand for antivirals, antimalarials, and bronchodilators is set to increase the need for APIs linked to COVID-19 drugs in the market prediction period.

What key areas define the segmentation of the global covid-19 drug associated apis Market?

The COVID-19 drug associated apis market covered in this report is segmented –

1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class

2) By Synthesis Type: Synthetic, Biotech

3) By Business Mode: Captive API, Merchant API

Subsegments:

1) By Antimalarials: Hydroxychloroquine, Chloroquine

2) By Bronchodilators: Beta-Agonists, Anticholinergics

3) By Antibiotics: Macrolides, Tetracyclines

4) By Antivirals: Remdesivir, Favipiravir, Lopinavir Or Ritonavir

5) By Other Drug Classes: Corticosteroids, Immunomodulators

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3248&type=smp

What are the top market players propelling the growth of the covid-19 drug associated apis industry?

Major companies operating in the COVID-19 drug associated apis market include Dr. Reddy’s Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd., Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.

What are the key trends shaping the future of the covid-19 drug associated apis market?

Players in the pharmaceutical sector manufacturing APIs associated with COVID-19 drugs are targeting capacity extension strategies to cater to the escalating demand resulting from growing COVID-19 cases worldwide. For instance, Merck & Co., Inc., an American pharmaceutical firm, through its latest collaboration with India’s Heavy Water Board in October 2023, is aiming to venture into the industry of deuterated raw compounds, presently valued at nearly $100 million. It possesses the potential to appreciate to $1 billion in the ensuing five to ten years. By providing superior quality compounds for the production of medicines, semiconductors, OLEDs, and electronics, Merck intends to contribute to India’s chemical, pharmaceutical, and technical domains. Currently, Avigan is undergoing clinical studies to examine its safety and effectiveness in treating COVID-19.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3248

What regions are dominating the covid-19 drug associated apis market growth?

North America was the largest region in the COVID-19 drug-associated APIs market in 2024. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated APIs market share during the forecast period. The regions covered in the COVID-19 drug associated APIs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

COVID-19 Rapid Test Kits Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/covid-19-rapid-test-kits-global-market-report

DTP Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

COVID-19 Rapid Test Kits Global Market Opportunities And Strategies To 2031

https://www.thebusinessresearchcompany.com/report/covid-19-rapid-test-kits-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: